Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • emc易倍官网入口Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • emc易倍官网入口Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • emc易倍官网入口Shareholder Information
    • Subscribe
    • emc易倍官网入口Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • emc易倍官网入口Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • emc易倍官网入口 China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • emc易倍官网入口 Germany
    • emc易倍官网入口 France
    • Nordics
    • Greece
    • emc易倍官网入口 Italy
    • Netherlands
    • emc易倍官网入口 Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • emc易倍官网入口Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • emc易倍官网入口Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • emc易倍官网入口Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • emc易倍官网入口Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • emc易倍官网入口Collaborate with us
  • Stories
  1. Home
  2. emc易倍官网入口Newsroom – Press Releases

emc易倍官网入口

emc易倍官网入口

Topics

Period

recent search

Reset

Showing: 1 – 5 of 247 Press Releases

28 May 2026

28 May 2026

Download New late-breaking data reinforces IQIRVO?’s impact on ALP, fatigue and pruritus in PBC
New late-breaking data reinforces IQIRVO?’s impact on ALP, fatigue and pruritus in PBC

19 May 2026

19 May 2026

Download Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with upper limb spasticity
Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with upper limb spasticity

16 May 2026

16 May 2026

Download Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

15 May 2026

15 May 2026

Download Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC
Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

14 May 2026

14 May 2026

Download Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium

  • 1
  • 2
  • …
  • 50
Your dedicated contacts
Sally Bain

Head of Global Media Relations

  • Phone Number
  • emc易倍官网入口+1 857 320 0517
  • Email Address
  • sally.bain@ipsen.com
Anne Liontas

France Media Relations

  • Phone Number
  • +33 7 67 34 72 96
  • Email Address
  • emc易倍官网入口anne.liontas.ext@ipsen.com
Stay updated
  • Register to receive our latest news

IPN price

€155.10

 €-2.80 (-1.77%)

  • Media Resources
  • Annual Report
  • emc易倍官网入口 Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-06-11 10:30:51